Improving rAAV production for viral vector manufacturing

The growing demand for gene therapies is placing increased pressure on viral vector manufacturing processes to deliver higher productivity while maintaining product quality and scalability.

In this on-demand webinar, we share data evaluating HyClone™ boost expression supplement for transient recombinant AAV (rAAV) production in HEK293 cell lines. We explore performance across multiple AAV serotypes, cell lines, media platforms, and scales, providing practical insights for upstream process development and manufacturing.

Watch to learn about:

• Current challenges in viral vector manufacturing
• Approaches to improving rAAV productivity in HEK293 cell lines
• Performance across multiple AAV serotypes and cell culture platforms
• Considerations for process scale-up from development to manufacturing
• Strategies to support more efficient upstream viral vector production workflows

Request a sample: https://cytiva.link/68d9a

Download the supporting application note: https://cytiva.link/l5wuv

Access the data file: https://cytiva.link/5ws8b